Developer docs
API playgroundTry for free, no card

Search company profiles

MBD

Full company profile

uuid00039bb

Namestring
MBD
Legal namestring
주식회사 엠비디 (MBD Co., Ltd.)
Websiteurl
mbdbiotech.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

MBD (Medical & Bio Decision) is a South Korea-based biotechnology company founded in 2015 that develops 3D cell culture platforms for precision oncology and drug development. Its core technology, branded as Cellvitro, uses alginate or matrigel-based extracellular matrix environments in micropillar/well chip and 384/96-well plate formats to overcome the predictive limitations of conventional 2D cell culture, with a chip architecture that allows 100% media exchange without residues. The integrated platform includes the ASFA Spotter (non-contact high-speed liquid dispenser capable of handling viscous ECM samples at a 20nL minimum volume), the ASFA Scanner (high-content imaging system with automated XYZ stage and Cell Ez Analysis software for quantitative analysis), and sample preparation equipment (Chopper for tissue dissociation and Shaker with heating function).

MBD monetizes through four distinct revenue streams: (1) laboratory equipment and consumables sales (Cellvitro chips/plates, ASFA Spotter, ASFA Scanner, Chopper, Shaker); (2) clinical drug sensitivity testing services — the OncoSensi Test — contracted with Korean hospitals to guide personalized anti-cancer treatment; (3) contract research organization (CRO) services for pharmaceutical companies, including 3D-based high-throughput drug screening and CRISPR CAS/9 stable cell line development; and (4) technology licensing for international commercialization, exemplified by the 2025 Kiyatec agreement covering the U.S. market. Customer segments span pharmaceutical companies (e.g., Eli Lilly hepatotoxicity assay collaboration, JW C&C anticancer drug development), tertiary hospitals (Samsung Medical Center, Seoul Asan Hospital, Seoul St. Mary's, Ajou University Hospital, with OncoSensi Test deployed at 33 sites by December 2025), research institutes (Luxembourg Institute of Health, Vanderbilt UMC, UCSF, Rensselaer Polytechnic Institute), and ultimately cancer patients receiving personalized treatment recommendations. Distribution is sales-led B2B: direct enterprise sales in Korea combined with international licensing and joint-research partnerships (Kiyatec, CytoGen Japan, Charité Germany) for cross-border expansion.

Short descriptiontext

MBD is a South Korea-based biotechnology company that develops 3D cell culture platforms (Cellvitro chips, ASFA Spotter/Scanner) and OncoSensi Test drug sensitivity services for hospitals, pharmaceutical companies, and research institutes in precision oncology.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSuwon, South Korea
HQ citystring
Suwon
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
3D cell culture, drug sensitivity testing, precision medicine platforms, laboratory automation equipment, cancer diagnostic services
Industry3 codes
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
NAICS code4 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Analytical Laboratory Instrument Manufacturing334516
  • Surgical and Medical Instrument Manufacturing339112
  • Medical Equipment and Supplies Manufacturing3391
SIC code4 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Laboratory Analytical Instruments3826
  • Services-Medical Laboratories8071
  • Services-Testing Laboratories8734
Product category
3D Cell Culture and Precision Oncology Platforms
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Drug Sensitivity Testing Services
TypeProfessional Services
Description

Anti-cancer drug sensitivity test services (OncoSensi Test) contracted to hospitals. Revenue from laboratory testing services for personalized cancer treatment.

mbdbiotech.com
2Laboratory Equipment Sales
TypeHardware Sales
Description

Sale of 3D cell culture products including Cellvitro chips/plates, ASFA Spotter, ASFA Scanner, and sample preparation equipment (Chopper, Shaker).

mbdbiotech.com
3CRO Services
TypeProfessional Services
Description

Contract research organization services including drug screening and stable cell line development for pharmaceutical companies.

mbdbiotech.com
4Technology Licensing
TypeLicensing Royalties
Description

License-out agreements for technology platforms including 2025 Kiyatec technology licensing for U.S. market.

mbdbiotech.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Cellvitro
Description

3D Cell Culture Chip/Plate platform for cell biology research and drug screening

mbdbiotech.com
+3 more records
Core offering1 text field

MBD manufactures and sells a proprietary 3D cell culture platform (Cellvitro® chips/plates) along with automated dispensing (ASFA® Spotter) and high-content imaging (ASFA® Scanner) instruments used by pharmaceutical companies, hospitals, and research institutes for anti-cancer drug sensitivity testing and drug screening. The company also operates a contract research organization (CRO) service and runs OncoSensi Test, a clinical drug sensitivity testing service contracted with hospitals in Korea and being expanded internationally via licensing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • OncoSensi Test expanded to 33 hospitals in Korea
+3 more records
Product overview1 text field

MBD offers a unified platform centered on Cellvitro® 3D cell culture technology for precision medicine and new drug development. The ecosystem includes ASFA® Spotter for automated non-contact liquid dispensing, ASFA® Scanner for high-content imaging and analysis, and Sample Preparation equipment (Chopper and Shaker). These products serve pharmaceutical companies, hospitals, universities, and research institutes for anti-cancer drug sensitivity testing and efficacy/toxicity evaluation. The company also provides CRO services using the platform.

Product and service7 records
1Cellvitro®
Category3D Cell Culture Consumables
Description

3D cell culture chip and plate platform that provides an extracellular matrix environment based on alginate or matrigel, enabling 100% media exchange without residues. Used by pharmaceutical companies, hospitals, and research institutes for cell biology research and drug screening.

2ASFA® Spotter
CategoryLaboratory Automation Equipment
Description

Non-contact high-speed liquid dispensing device for cell biology research and drug screening; features On-the-Fly mode for automated 3D cell culture, dispensing viscous Alginate or Matrigel-based ECM with cells at a minimum volume of 20nL.

3ASFA® Scanner
CategoryLaboratory Imaging Equipment
Description

High-content imaging system for rapid acquisition and analysis of high-quality images of cells or biological tissues; equipped with auto focus, automatic XYZ stage for multi-pillar and well plate imaging, and Cell Ez Analysis software for quantitative analysis.

4Sample Preparation Equipment (Chopper and Shaker)
CategoryLaboratory Automation Equipment
Description

Sample preparation equipment including the Chopper for optimized tumoroid production (high-speed tissue dissociation within 5 minutes) and the Shaker with heating function (±10° Rocker Type, up to 45°C, 20–100 RPM) for use upstream of the Cellvitro platform.

5CRO Services
CategoryContract Research Services
Description

Contract research organization services including 3D-based high-throughput drug screening using the Cellvitro Pillar platform, Calcein AM viability testing, specific protein antibody staining via immunofluorescence, and stable cell line development using CRISPR Cas9 technology for gene editing.

6OncoSensi Test
CategoryClinical Diagnostic Services
Description

Anti-cancer drug sensitivity testing service that uses patient-derived cancer cells in 3D culture to identify optimal treatment options for individual cancer patients; contracted with hospitals as a precision oncology diagnostic service.

7Radiation Sensitivity Test Service
CategoryClinical Diagnostic Services
Description

Radiation sensitivity prediction service using patient-derived cancer cells in 3D culture to evaluate tumor response to radiotherapy and support personalized radiotherapy planning.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership16 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-01
Description

MOU signed for commercialization of Precision Cancer Medicine in Japan's healthcare market. Collaboration to expand MBD's precision cancer medicine services into Japan.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-13
Description

Strategic investment and partnership for U.S. commercial expansion. MBD's automation technology is being integrated into Kiyatec's Greenville, SC laboratory. The collaboration aims to accelerate launch of diagnostic panels for various cancers and improve operational efficiency for functional oncology testing.

3Central Bio Co., Ltd.
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-08-01
Description

MOU for development of a New Drug Candidate Evaluation Platform utilizing PDO and PDOX models.

mbdbiotech.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-01
Description

Established joint research laboratory with Charité Comprehensive Cancer Center in Germany for collaborative cancer research.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration on biochip platform research for turning biochips into personalized immunotherapy platforms for cancer patients. Working on screening treatment cocktails with chemotherapeutic drugs and monoclonal antibodies with NK cells.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Established joint research laboratory (2020). Export of ASFA Spotters. Collaboration on personalized cancer drug screening research.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research collaboration agreement for personalized cancer drug screening (2018). France-based partner.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration on MBD 3D chip-based hepatotoxicity assay development.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

MOU signed to develop innovative anticancer drugs using cancer organoid diagnosis platform.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Joint development contract for rare cancer treatment based on AI Model (2020).

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Clinical contract to validate solutions for prognosis/prediction of personalized cancer treatment (2022).

12Vanderbilt University Medical Center
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Export of ASFA Spotters (2023). Collaboration on personalized medicine research.

mbdbiotech.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research collaboration on head and neck cancer and colon cancer chemoradiotherapy correlation using MBD 3D drug screening system.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration on MBD 3D chip-based hepatotoxicity assay development.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Sales representative agreement signed in January 2017.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Participation in Japan's Monstar Project for cancer research.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Dutch organ-on-chip company offering 3D tissue models for drug screening and toxicology. Competes with MBD's 3D cell culture platform from a different technological angle.

TypeDirect peer
Description

U.S.-based functional precision oncology company offering 3D cell culture drug response prediction services for cancer patients. Directly comparable as a peer in clinical-grade functional oncology testing and is itself MBD's U.S. commercialization partner.

TypeDirect peer
Description

Provides patient-derived tumor models (PDX, organoids) and drug sensitivity testing services to pharma and oncology centers. Closely comparable service offering to MBD's OncoSensi Test with deeper U.S. footprint.

TypeDirect peer
Description

Functional precision oncology company using patient-derived tumor models for individualized drug response prediction. Direct overlap with MBD's hospital-facing OncoSensi service model.

TypeBroad incumbent
Description

Global preclinical CRO offering PDX, organoid, and 3D cell-based drug screening services to pharma. Comparable in CRO drug screening services and oncology model platform but at significantly larger scale.

TypeBroad incumbent
Description

Major manufacturer of high-content imaging and laboratory automation instruments used in drug discovery and cell biology. Comparable in the ASFA Scanner product category as a much larger incumbent.

TypeBroad incumbent
Description

Global leader in laboratory automation, liquid handling, and detection instruments for life science research. Directly comparable in the non-contact liquid dispensing and imaging instrument categories (ASFA Spotter/Scanner).

TypeBroad incumbent
Description

Manufacturer of precision liquid handling automation, lab robotics, and detection instruments. Overlaps with MBD's ASFA Spotter automation offering as a much larger, established incumbent.

TypeEmerging player
Description

Developer of organ-on-chip platforms for preclinical drug testing and disease modeling. Competes conceptually with MBD's 3D cell culture approach and represents a next-generation alternative.

TypeBroad incumbent
Description

Global leader in cell and gene therapy manufacturing, cell culture services, and biological products. Adjacent peer in cell culture platforms with broader CDMO scale.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers14 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance12 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MBD

3D Cell Culture and Precision Oncology Platformsmbdbiotech.com

MBD is a South Korea-based biotechnology company that develops 3D cell culture platforms (Cellvitro chips, ASFA Spotter/Scanner) and OncoSensi Test drug sensitivity services for hospitals, pharmaceutical companies, and research institutes in precision oncology.

What MBD does

MBD (Medical & Bio Decision) is a South Korea-based biotechnology company founded in 2015 that develops 3D cell culture platforms for precision oncology and drug development. Its core technology, branded as Cellvitro, uses alginate or matrigel-based extracellular matrix environments in micropillar/well chip and 384/96-well plate formats to overcome the predictive limitations of conventional 2D cell culture, with a chip architecture that allows 100% media exchange without residues. The integrated platform includes the ASFA Spotter (non-contact high-speed liquid dispenser capable of handling viscous ECM samples at a 20nL minimum volume), the ASFA Scanner (high-content imaging system with automated XYZ stage and Cell Ez Analysis software for quantitative analysis), and sample preparation equipment (Chopper for tissue dissociation and Shaker with heating function).

MBD monetizes through four distinct revenue streams: (1) laboratory equipment and consumables sales (Cellvitro chips/plates, ASFA Spotter, ASFA Scanner, Chopper, Shaker); (2) clinical drug sensitivity testing services — the OncoSensi Test — contracted with Korean hospitals to guide personalized anti-cancer treatment; (3) contract research organization (CRO) services for pharmaceutical companies, including 3D-based high-throughput drug screening and CRISPR CAS/9 stable cell line development; and (4) technology licensing for international commercialization, exemplified by the 2025 Kiyatec agreement covering the U.S. market. Customer segments span pharmaceutical companies (e.g., Eli Lilly hepatotoxicity assay collaboration, JW C&C anticancer drug development), tertiary hospitals (Samsung Medical Center, Seoul Asan Hospital, Seoul St. Mary's, Ajou University Hospital, with OncoSensi Test deployed at 33 sites by December 2025), research institutes (Luxembourg Institute of Health, Vanderbilt UMC, UCSF, Rensselaer Polytechnic Institute), and ultimately cancer patients receiving personalized treatment recommendations. Distribution is sales-led B2B: direct enterprise sales in Korea combined with international licensing and joint-research partnerships (Kiyatec, CytoGen Japan, Charité Germany) for cross-border expansion.

MBD firmographics

Firmographics
Name
MBD
Legal name
주식회사 엠비디 (MBD Co., Ltd.)
Website
https://mbdbiotech.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
MBD is a South Korea-based biotechnology company that develops 3D cell culture platforms (Cellvitro chips, ASFA Spotter/Scanner) and OncoSensi Test drug sensitivity services for hospitals, pharmaceutical companies, and research institutes in precision oncology.
Ownership category
akta.pro rank

MBD industry classification

Industry
Product category
3D Cell Culture and Precision Oncology Platforms
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516), Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826), Services-Medical Laboratories (8071), Services-Testing Laboratories (8734)
akta.pro industry
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)

Keywords

  • 3D cell culture
  • Drug sensitivity testing
  • Precision medicine platforms
  • Laboratory automation equipment
  • Cancer diagnostic services

Where MBD is headquartered

Location

Headquarters

HQ city
Suwon
HQ country
South Korea
HQ region
Asia

Offices2 records

Markets served

MBD business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Drug Sensitivity Testing Services: Anti-cancer drug sensitivity test services (OncoSensi Test) contracted to hospitals. Revenue from laboratory testing services for personalized cancer treatment.
  2. Laboratory Equipment Sales: Sale of 3D cell culture products including Cellvitro chips/plates, ASFA Spotter, ASFA Scanner, and sample preparation equipment (Chopper, Shaker).
  3. CRO Services: Contract research organization services including drug screening and stable cell line development for pharmaceutical companies.
  4. Technology Licensing: License-out agreements for technology platforms including 2025 Kiyatec technology licensing for U.S. market.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

MBD product offering

Product offering

Core offering

MBD manufactures and sells a proprietary 3D cell culture platform (Cellvitro® chips/plates) along with automated dispensing (ASFA® Spotter) and high-content imaging (ASFA® Scanner) instruments used by pharmaceutical companies, hospitals, and research institutes for anti-cancer drug sensitivity testing and drug screening. The company also operates a contract research organization (CRO) service and runs OncoSensi Test, a clinical drug sensitivity testing service contracted with hospitals in Korea and being expanded internationally via licensing.

Product overview

MBD offers a unified platform centered on Cellvitro® 3D cell culture technology for precision medicine and new drug development. The ecosystem includes ASFA® Spotter for automated non-contact liquid dispensing, ASFA® Scanner for high-content imaging and analysis, and Sample Preparation equipment (Chopper and Shaker). These products serve pharmaceutical companies, hospitals, universities, and research institutes for anti-cancer drug sensitivity testing and efficacy/toxicity evaluation. The company also provides CRO services using the platform.

Differentiator

Problem solved

Functional benefit

Brands

  • Cellvitro: 3D Cell Culture Chip/Plate platform for cell biology research and drug screening
  • ASFA Spotter
  • ASFA Scanner
  • OncoSensi Test

Products and services

  • Cellvitro® 3D cell culture chip and plate platform that provides an extracellular matrix environment based on alginate or matrigel, enabling 100% media exchange without residues. Used by pharmaceutical companies, hospitals, and research institutes for cell biology research and drug screening.
  • ASFA® Spotter Non-contact high-speed liquid dispensing device for cell biology research and drug screening; features On-the-Fly mode for automated 3D cell culture, dispensing viscous Alginate or Matrigel-based ECM with cells at a minimum volume of 20nL.
  • ASFA® Scanner High-content imaging system for rapid acquisition and analysis of high-quality images of cells or biological tissues; equipped with auto focus, automatic XYZ stage for multi-pillar and well plate imaging, and Cell Ez Analysis software for quantitative analysis.
  • Sample Preparation Equipment (Chopper and Shaker) Sample preparation equipment including the Chopper for optimized tumoroid production (high-speed tissue dissociation within 5 minutes) and the Shaker with heating function (±10° Rocker Type, up to 45°C, 20–100 RPM) for use upstream of the Cellvitro platform.
  • CRO Services Contract research organization services including 3D-based high-throughput drug screening using the Cellvitro Pillar platform, Calcein AM viability testing, specific protein antibody staining via immunofluorescence, and stable cell line development using CRISPR Cas9 technology for gene editing.
  • OncoSensi Test Anti-cancer drug sensitivity testing service that uses patient-derived cancer cells in 3D culture to identify optimal treatment options for individual cancer patients; contracted with hospitals as a precision oncology diagnostic service.
  • Radiation Sensitivity Test Service Radiation sensitivity prediction service using patient-derived cancer cells in 3D culture to evaluate tumor response to radiotherapy and support personalized radiotherapy planning.

Quantifiable outcome

  • OncoSensi Test expanded to 33 hospitals in Korea
  • +3 more outcomes

Companies that use MBD

Customer profile

Named customers14 records

Segments4 records

Ideal customer profiles3 records

MBD technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature6 records

MBD partnerships and signals

Strategic signal

Partnerships

16 partnerships are on record, tiered core and minor.

  • CytoGen JapancoreStrategic or Co-development Partner · 1 December 2025MOU signed for commercialization of Precision Cancer Medicine in Japan's healthcare market. Collaboration to expand MBD's precision cancer medicine services into Japan.
  • KiyateccoreStrategic or Co-development Partner · 13 November 2025Strategic investment and partnership for U.S. commercial expansion. MBD's automation technology is being integrated into Kiyatec's Greenville, SC laboratory. The collaboration aims to accelerate launch of diagnostic panels for various cancers and improve operational efficiency for functional oncology testing.
  • Central Bio Co., Ltd.minorStrategic or Co-development Partner · 1 August 2025MOU for development of a New Drug Candidate Evaluation Platform utilizing PDO and PDOX models.
  • Charité Comprehensive Cancer CentercoreStrategic or Co-development Partner · 1 July 2025Established joint research laboratory with Charité Comprehensive Cancer Center in Germany for collaborative cancer research.
  • Rensselaer Polytechnic InstitutecoreStrategic or Co-development PartnerCollaboration on biochip platform research for turning biochips into personalized immunotherapy platforms for cancer patients. Working on screening treatment cocktails with chemotherapeutic drugs and monoclonal antibodies with NK cells.
  • Luxembourg Institute of HealthcoreStrategic or Co-development PartnerEstablished joint research laboratory (2020). Export of ASFA Spotters. Collaboration on personalized cancer drug screening research.
  • KsilinkminorStrategic or Co-development PartnerResearch collaboration agreement for personalized cancer drug screening (2018). France-based partner.
  • Eli Lilly and CompanyminorStrategic or Co-development PartnerCollaboration on MBD 3D chip-based hepatotoxicity assay development.
  • JW C&C New Drug Research InstituteminorStrategic or Co-development PartnerMOU signed to develop innovative anticancer drugs using cancer organoid diagnosis platform.
  • AzothbiominorStrategic or Co-development PartnerJoint development contract for rare cancer treatment based on AI Model (2020).
  • GC LabsminorStrategic or Co-development PartnerClinical contract to validate solutions for prognosis/prediction of personalized cancer treatment (2022).
  • Vanderbilt University Medical CenterminorStrategic or Co-development PartnerExport of ASFA Spotters (2023). Collaboration on personalized medicine research.
  • University of California San FranciscominorStrategic or Co-development PartnerResearch collaboration on head and neck cancer and colon cancer chemoradiotherapy correlation using MBD 3D drug screening system.
  • Cleveland State UniversityminorStrategic or Co-development PartnerCollaboration on MBD 3D chip-based hepatotoxicity assay development.
  • ThermoFisher ScientificminorChannel Partner/ Reseller/ DistributorSales representative agreement signed in January 2017.
  • NCCHE (Japan)minorStrategic or Co-development PartnerParticipation in Japan's Monstar Project for cancer research.

Scale indicators8 records

Recent moves8 records

Expansion highlights7 records

MBD competitors and assessment

Company assessment

Emerging players

  • Mimetas: Dutch organ-on-chip company offering 3D tissue models for drug screening and toxicology. Competes with MBD's 3D cell culture platform from a different technological angle.
  • Emulate: Developer of organ-on-chip platforms for preclinical drug testing and disease modeling. Competes conceptually with MBD's 3D cell culture approach and represents a next-generation alternative.

Direct peers

  • Kiyatec: U.S.-based functional precision oncology company offering 3D cell culture drug response prediction services for cancer patients. Directly comparable as a peer in clinical-grade functional oncology testing and is itself MBD's U.S. commercialization partner.
  • Champions Oncology: Provides patient-derived tumor models (PDX, organoids) and drug sensitivity testing services to pharma and oncology centers. Closely comparable service offering to MBD's OncoSensi Test with deeper U.S. footprint.
  • Certis Oncology Solutions: Functional precision oncology company using patient-derived tumor models for individualized drug response prediction. Direct overlap with MBD's hospital-facing OncoSensi service model.

Broad incumbents

  • Crown Bioscience (JSR Life Sciences): Global preclinical CRO offering PDX, organoid, and 3D cell-based drug screening services to pharma. Comparable in CRO drug screening services and oncology model platform but at significantly larger scale.
  • Molecular Devices (Danaher): Major manufacturer of high-content imaging and laboratory automation instruments used in drug discovery and cell biology. Comparable in the ASFA Scanner product category as a much larger incumbent.
  • Tecan: Global leader in laboratory automation, liquid handling, and detection instruments for life science research. Directly comparable in the non-contact liquid dispensing and imaging instrument categories (ASFA Spotter/Scanner).
  • Hamilton Company: Manufacturer of precision liquid handling automation, lab robotics, and detection instruments. Overlaps with MBD's ASFA Spotter automation offering as a much larger, established incumbent.
  • Lonza Group: Global leader in cell and gene therapy manufacturing, cell culture services, and biological products. Adjacent peer in cell culture platforms with broader CDMO scale.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

MBD compliance and trust

Trust signal

Compliance12 records

MBD financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MBD leadership team

Management profile

Number of profiles

Profiles1 record

MBD funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MBD M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MBD

What does MBD do?

MBD manufactures and sells a proprietary 3D cell culture platform (Cellvitro® chips/plates) along with automated dispensing (ASFA® Spotter) and high-content imaging (ASFA® Scanner) instruments used by pharmaceutical companies, hospitals, and research institutes for anti-cancer drug sensitivity testing and drug screening. The company also operates a contract research organization (CRO) service and runs OncoSensi Test, a clinical drug sensitivity testing service contracted with hospitals in Korea and being expanded internationally via licensing.

Is MBD a public or private company?

MBD is a private company. It is classified as venture growth investor backed and is currently operating.

When was MBD founded?

MBD was founded in 2015. It employs 11 to 50 people.

Where is MBD based?

MBD is headquartered in Suwon, South Korea, in the Asia region.

How does MBD make money?

Four revenue lines are on record. Drug Sensitivity Testing Services are the primary driver. The others are laboratory Equipment Sales, CRO Services and technology Licensing.

Who are MBD's main competitors?

Emerging players on record are Mimetas and Emulate. Direct peers are Kiyatec, Champions Oncology and Certis Oncology Solutions. Broad incumbents are Crown Bioscience (JSR Life Sciences), Molecular Devices (Danaher), Tecan, Hamilton Company and Lonza Group.

Does MBD have an API?

No public API is recorded for MBD.

What industry is MBD in?

MBD's product category is 3D Cell Culture and Precision Oncology Platforms. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Nate'Humidity and Temperature Control Equipment Manufacturing' Melcon and two other companies pass KOSDAQ listing review: Nate NewsThe Korea Exchange's KOSDAQ Market Headquarters approved the preliminary listing review for three companies—Melcon, Lab Up, and MBD—following deliberation by the KOSDAQ Market Listing Committee. Melcon, a special-purpose machinery manufacturer established in 2003, reported 41.83 billion won in consolidated revenue and 6.15 billion won in operating profit last year, with Daishin Securities as its underwriter. Lab Up (AI infrastructure software, 6.71B won revenue, NH Investment & Securities underwriter) and MBD (medical devices, 1.52B won revenue but 5.63B won operating loss, Hana Securities underwriter) were also approved for the listing process.뉴스톱‘코스닥 노크’한 엠비디...VC 회수 기대감 속 기술특례 시험대 - 뉴스톱엠비디 filed for 코스닥 preliminary listing on October 10, with 14.32 million shares planned. The company has raised over 415 billion won since 2018, but its IPO success depends on converting technology into revenue. Analysts see the key to success in demonstrating commercialization potential.Business Wire BlogKiyatec Secures Strategic Investment from South Korean Partner MBD to Accelerate U.S. Commercial ExpansionKiyatec closed a strategic investment round led by South Korean partner MBD to accelerate its U.S. commercial expansion. The partnership will integrate MBD's automated platform into Kiyatec's CLIA/CAP labs in Greenville, SC, to enhance throughput and quality control. The funds will support commercial expansion, AI tool integration, and clinical evidence generation for reimbursement.YahooKiyatec Secures Strategic Investment from South Korean Partner MBD to Accelerate U.S. Commercial ExpansionKiyatec announced a strategic investment from South Korean technology company MBD, aimed at expanding its U.S. testing capabilities and accelerating the launch of cancer diagnostic panels. The partnership involves integrating MBD's automated platform technology into Kiyatec's Greenville laboratory to improve throughput and quality while expanding to multiple cancer types.